Global efforts to eliminate malaria have saved an estimated 3.3 million lives since 2000, reducing malaria mortality rates by 45 per cent globally, according to the World malaria report 2013 published by the World Health Organization (WHO).
British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.
An experimental malaria vaccine proved highly effective in a small, early-stage clinical trial in people, raising hope in the global effort to combat the deadly disease, US researchers reported on Thursday in the journal Science.
Global funding for the fight against malaria has stalled in the past two years, threatening to reverse what the World Health Organisation (WHO) says are "remarkable recent gains" in the battle to control one of the world's leading
A GlaxoSmithKline experimental malaria vaccine touted as a new weapon in the fight to eradicate the disease proved only 30 percent effective when given to babies as part Africa's largest ever clinical trial.
Malaria remains one of the most deadly infectious diseases in the world and recent estimates suggest that many more people are dying of the disease each year than previously believed, said an expert.
The disease causes 1.24 million deaths
Drug-resistant malaria could spread from southeast Asia to Africa within months, putting millions of children's lives at risk, a leading expert warned.
Nicholas White, professor of tropical medicine at Mahidol University in Bangkok, called
The world could stop malaria deaths by 2015 if massive investment is made to ramp up control measures, including wider use of insecticide-treated mosquito nets, the World Health Organisation (WHO) said on Tuesday.
Progress has been made ov
Global funding for malaria is less than half the $4.9 billion needed in 2010 to prevent and treat the disease that kills around 850,000 people a year, a study showed on Saturday.
Researchers writing in The Lancet medical journal said that
Dutch biotechnology firm Crucell said on Tuesday it had agreed with Britain's GlaxoSmithKline to jointly develop a malaria vaccine candidate.
The deal is an extension to an earlier programme agreed in October 2003 between Crucell, GSK and